Elanco Animal Health (ELAN) to Release Quarterly Earnings on Tuesday

Elanco Animal Health (NYSE:ELAN - Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect Elanco Animal Health to post earnings of $0.16 per share and revenue of $1.01 billion for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Elanco Animal Health Stock Performance

NYSE:ELAN traded down $0.11 during mid-day trading on Friday, reaching $11.02. The company's stock had a trading volume of 7,323,373 shares, compared to its average volume of 4,589,125. Elanco Animal Health has a 12-month low of $10.77 and a 12-month high of $18.80. The firm's fifty day moving average price is $11.80 and its two-hundred day moving average price is $13.09. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a market cap of $5.45 billion, a P/E ratio of 27.54, a PEG ratio of 2.53 and a beta of 1.42.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ELAN. Stifel Nicolaus decreased their target price on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a research report on Friday. UBS Group began coverage on Elanco Animal Health in a research report on Monday, December 9th. They issued a "buy" rating and a $18.00 target price for the company. Leerink Partnrs raised Elanco Animal Health to a "hold" rating in a research report on Monday, December 2nd. Morgan Stanley decreased their target price on Elanco Animal Health from $15.00 to $14.00 and set an "equal weight" rating for the company in a research report on Wednesday, January 29th. Finally, Barclays boosted their price target on Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $16.00.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.